1Piccart M,Parker LM,Pritchard KI.Oestrogen receptor downregulation:an opportunity for extending the window of endocrine therapy in advanced breast cancer[J].Ann Oncol,2003,14(7):1017-1025. 被引量：1
2Buzdar A,Hayes D,El-Khoudary A,et al.Phase Ⅲ randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer[J].Breast Cancer Res Treat 2002,73(2):161. 被引量：1
3Buzdar A,O'Shaughnessy JA,Booser DJ,et al.Phase Ⅱ,Randomized,Double-Blind Study of Two Dose Levels of Arzoxifene in Patients with Locally Advanced or Metastatic Breast Cancer[J].J Clin Oncol,2003,21(6):1007. 被引量：1
4Howell A,Robertson JFR,Abram P,et al.Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy:a multination,double-blind,randomized trial[J].J Clin Oncol,2004,22:1605-1613. 被引量：1
5Vergote I,Abram P.Fulvestrant,a new treatment option for advanced breast cancer:tolerability versus existing agents[J].Ann Oncol,2006,17(2):200-204. 被引量：1
6Milla Santos A,Milla L,Portella J,et al.Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer:a prospective,randomized,phase Ⅲ study[J].Am J Clin Oncol,2003,26(3):317-322. 被引量：1
7Thurlimann B,Hess D,Koberle D,et al.Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer:results of the double-blind Cross-over SAKK trial 21/ 9522a sub2study of the TARGET (Tamoxifen or 'Arimidex'Randomized Group Efficacy and Tolerability) trial[J].Breast Cancer Res Treat,2004,85(3):247-254. 被引量：1
8Buzdar A,Douma J,Davidson N,et al.Phase Ⅲ,multicenter,double-blind,randomized study of letrozole,an aromatase inhibitor,for advanced breast cancer versus megestrol acetate[J].J Clin Oncol,2001,19(14):3357. 被引量：1
9Paridaens R,Dirix L,Lohrisch C,et al.Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer[J].Ann Oncol,2003,14(9):1391-1398. 被引量：1
10Lonning PE,Bajetta E,Murray R,et al.Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitor:a phase Ⅱ trial[J].J Clin Oncol,2000,18(11):2234-2244. 被引量：1
